Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242959 | 1.00 | HCAR2 (0.47) | HCAR2MAPTL3MBTL1CA12CA1 | |
| SCHEMBL13285790 | 0.88 | HCAR2 (0.43) | HCAR2MAPTL3MBTL1CA12CA1 | |
| SCHEMBL8179462 | 0.84 | MAPT (0.59) | HCAR2MAPTL3MBTL1CA12CA1 | |
| SCHEMBL19637533 | 0.79 | HCAR2 (0.48) | HCAR2MAPTL3MBTL1CA12CA1 | |
| SCHEMBL13182144 | 0.75 | ALDH1A1 (0.40) | ALDH1A1LMNA | |
| Diethyl Maleate SCHEMBL2015896 | 0.72 | HCAR2 (0.80) | HCAR2MAPTCA12CA1CA2 | |
| Diethyl Maleate SCHEMBL43033 | 0.72 | HCAR2 (0.80) | HCAR2MAPTCA12CA1CA2 | |
| Diethyl Maleate SCHEMBL2015895 | 0.72 | HCAR2 (0.80) | HCAR2MAPTCA12CA1CA2 | |
| Diethyl Maleate SCHEMBL42602 | 0.72 | HCAR2 (0.80) | HCAR2MAPTCA12CA1CA2 | |
| Diethyl Maleate SCHEMBL60423 | 0.72 | HCAR2 (0.80) | HCAR2MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183019-B2 | (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine; enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone; for purine nucleoside phosphorylase (PNP) inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-22 | — | — | US | disclosed |
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2008-11-13 | — | — | US | disclosed |
| WO-2007048225-A1 | A 4-OXO-1- (3-SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4-INHIBITOR AND A METHOD OF PREPARING SAME | MERCK FROSST CANADA LTD. (CA) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050576-A2 | A METHOD OF PREPARING A 4-OXO-1- (3 SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3- CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITOR | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | HPD, DHPS, CYP3A5 | HCAR2 1091/4885MAPT 4323/4885L3MBTL1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.